Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Pegloticase

Nature Reviews Drug Discovery volume 10, pages 17–18 (2011)Cite this article

Subjects

An Erratum to this article was published on 01 February 2011

This article has been updated

Abstract

In September 2010, pegloticase (Krystexxa; Savient Pharmaceuticals), a recombinant urate oxidase conjugated to polyethylene glycol (PEG), was approved by the US Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pathogenesis of gout and targets for therapeutic intervention.

Change history

  • 18 January 2011

    Naomi Schlesinger is affiliated with the Robert Wood Johnson Medical School, New Jersey, USA, not the University Hospital, as stated. This has been corrected in the online version.

References

  1. Richette, P. & Bardin, T. Gout. Lancet 375, 318–328 (2010).

    Article  CAS  Google Scholar 

  2. Palmer, D. G., Highton, J. & Hessian, P. A. Development of the gout tophus. An hypothesis. Am. J. Clin. Pathol. 91, 190–195 (1989).

    Article  CAS  Google Scholar 

  3. Burns, C. M. & Wortmann, R. L. Gout therapeutics: new drugs for an old disease. Lancet 16 Aug 2010 (doi:10.1016/S0140-6736(10)60665-4).

    Article  CAS  Google Scholar 

  4. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).

    Article  CAS  Google Scholar 

  5. Pascual, E. et al. Febuxostat. Nature Rev. Drug Discov. 8, 191–192 (2008).

    Article  Google Scholar 

  6. Sundy, J. S. et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56, 1021–1028 (2007).

    Article  CAS  Google Scholar 

  7. Sundy, J. S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 58, 2882–2891 (2008).

    Article  Google Scholar 

  8. US Food and Drug Administration. FDA labelling information — Krystexxa (pegloticase). FDA website [online], (2010).

  9. Thiele, R. G. & Schlesinger, N. Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout. Arthritis Rheum. 60, S565 (2009).

    Google Scholar 

  10. Mandel, D. R. et al. Use of pegloticase in chronic gout refractory to conventional therapy is associated with significant clinical benefit: tender joint and swollen joint counts and patient global assessment (Health Assessment Questionnaire). Arthritis Rheum. 62, S166 (2010).

    Google Scholar 

  11. Schlesinger, N. et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 62, S2087 (2010)

    Google Scholar 

  12. Terkeltaub, R. et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, S152 (2010).

    Google Scholar 

  13. Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).

    Article  CAS  Google Scholar 

  14. IMS MIDAS (2010).

  15. Richter, S. & Ekas, L. Collins Stewart Report on Savient Pharmaceuticals. (Collins Stewart, 5 Nov 2010),

    Google Scholar 

  16. Werher, C. Summer Street Report on Savient Pharmaceuticals. (Summer Street, 8 Nov 2010).

    Google Scholar 

Download references

Acknowledgements

U.Y. would like to thank D. Hanicq for assistance in data collection.

Author information

Authors and Affiliations

  1. Naomi Schlesinger is at the Department of Medicine, PO Box 19, Robert Wood Johnson Medical School, New Jersey 08903–0019, USA. schlesna@umdnj.edu,

    Naomi Schlesinger

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Naomi Schlesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Naomi Schlesinger has acted as a consultant for and received grants from Novartis, has been part of the speakers bureau for Takeda, and has participated in advisory boards for novartis, Takeda, URL Pharma, Savient and RX Enzyme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlesinger, N., Yasothan, U. & Kirkpatrick, P. Pegloticase. Nat Rev Drug Discov 10, 17–18 (2011). https://doi.org/10.1038/nrd3349

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3349

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research